{"entity":{"id":"nct02579564","kind":"trial","name":"Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients","aka":[],"tldr":"A phase 3 trial of Gemcitabine, Vinorelbine, Paclitaxel / nab-paclitaxel, Pemetrexed, H101 oncolytic adenovirus, Recombinant human endostatin and Cisplatin in Non-small-cell lung cancer, run by Xinqiao Hospital of Chongqing, with a status the registry has not verified recently.","summary":"Systemic Chemotherapy Combined With Recombinant Human Adenovirus Type 5 and Endostatin Injections for Treatment Malignant Hydrothorax in NSCLC Patients is a phase 3 interventional study registered as NCT02579564 by Xinqiao Hospital of Chongqing, with 134 participants planned, started 2016-10 and due to reach its primary completion in 2018-06. Interventions recorded: Gemcitabine, Vinorelbine, Paclitaxel, Pemetrexed, Oncorine, Endostar, Cisplatin. Conditions recorded: Malignant Hydrothorax, Non Small Cell Lung Cancer.\n\nLinked to the drug H101 oncolytic adenovirus because the registry names it among its interventions and Non-small-cell lung cancer among its conditions. Registry record only: no result has been read by an editor.","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT02579564","url":"https://clinicaltrials.gov/study/NCT02579564"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":["gemcitabine","vinorelbine","paclitaxel","pemetrexed","h101-oncolytic-adenovirus","recombinant-human-endostatin","cisplatin"],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT02579564","phase":"3","setting":"Systemic Chemotherapy Combined With Thoracic Cavity Perfusion of Recombinant Human Adenovirus Type 5 and Endostatin Injections Versus Cisplatin for Treatment Malignant Hydrothorax in Non Small Cell Lung Cancer (NSCLC) Patients: A Multi-center, Randomized, Controlled Clinical Trial","sponsor":"Xinqiao Hospital of Chongqing","enrolled":134,"enrolledBasis":"registry","outcomes":[]},"route":"/trials/nct02579564/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"drug":[{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"gemcitabine","kind":"drug","name":"Gemcitabine","route":"/drugs/gemcitabine/"},{"id":"h101-oncolytic-adenovirus","kind":"drug","name":"H101 oncolytic adenovirus","route":"/drugs/h101-oncolytic-adenovirus/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"},{"id":"recombinant-human-endostatin","kind":"drug","name":"Recombinant human endostatin","route":"/drugs/recombinant-human-endostatin/"},{"id":"vinorelbine","kind":"drug","name":"Vinorelbine","route":"/drugs/vinorelbine/"}]}}